Which has higher valuation & earnings, GRFS or SEPN?

Grifols has higher revenue and earnings than Septerna. Septerna is trading at a lower price-to-earnings ratio than Grifols, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Grifols $8.51B 0.59 $454.82M $0.19 38.58 Septerna $45.95M 29.83 -$48.88M -$0.81 N/A

Is GRFS or SEPN more profitable?

Grifols has a net margin of 5.54% compared to Septerna's net margin of -49.88%. Grifols' return on equity of 6.21% beat Septerna's return on equity. Company Net Margins Return on Equity Return on Assets Grifols 5.54% 6.21% 2.39% Septerna -49.88% -12.72% -8.87%

Does the media refer more to GRFS or SEPN?

In the previous week, Septerna had 2 more articles in the media than Grifols. MarketBeat recorded 4 mentions for Septerna and 2 mentions for Grifols. Grifols' average media sentiment score of 1.64 beat Septerna's score of -0.03 indicating that Grifols is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Grifols 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Septerna 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to XENE or SEPN?

In the previous week, Septerna had 2 more articles in the media than Xenon Pharmaceuticals. MarketBeat recorded 4 mentions for Septerna and 2 mentions for Xenon Pharmaceuticals. Xenon Pharmaceuticals' average media sentiment score of 0.85 beat Septerna's score of -0.03 indicating that Xenon Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Xenon Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Septerna 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has better earnings and valuation, SEPN or CGON?

Septerna has higher revenue and earnings than CG Oncology. Septerna is trading at a lower price-to-earnings ratio than CG Oncology, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Septerna $45.95M 29.83 -$48.88M -$0.81 N/A CG Oncology $4.04M 1,187.64 -$160.99M -$2.33 N/A

Is SEPN or CGON more profitable?

CG Oncology has a net margin of 0.00% compared to Septerna's net margin of -49.88%. Septerna's return on equity of -12.72% beat CG Oncology's return on equity. Company Net Margins Return on Equity Return on Assets Septerna -49.88% -12.72% -8.87% CG Oncology N/A -23.33% -22.24%

Does the media prefer SEPN or CGON?

In the previous week, Septerna and Septerna both had 4 articles in the media. Septerna's average media sentiment score of -0.03 beat CG Oncology's score of -0.37 indicating that Septerna is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Septerna 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral CG Oncology 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

Does the media refer more to APGE or SEPN?

In the previous week, Apogee Therapeutics had 3 more articles in the media than Septerna. MarketBeat recorded 7 mentions for Apogee Therapeutics and 4 mentions for Septerna. Apogee Therapeutics' average media sentiment score of 0.62 beat Septerna's score of -0.03 indicating that Apogee Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Apogee Therapeutics 3 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Septerna 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor DNTH or SEPN?

In the previous week, Dianthus Therapeutics had 3 more articles in the media than Septerna. MarketBeat recorded 7 mentions for Dianthus Therapeutics and 4 mentions for Septerna. Dianthus Therapeutics' average media sentiment score of 0.50 beat Septerna's score of -0.03 indicating that Dianthus Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Dianthus Therapeutics 3 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Septerna 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Septerna (SEPN) Competitors

$30.41 -0.74 (-2.38%)

Closing price 04:00 PM Eastern

Extended Trading

$30.44 +0.03 (+0.10%)

As of 05:19 PM Eastern

Compare

SEPN vs. GRFS, XENE, CGON, APGE, and DNTH

Should you buy Septerna stock or one of its competitors? MarketBeat compares Septerna with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Septerna include Grifols (GRFS), Xenon Pharmaceuticals (XENE), CG Oncology (CGON), Apogee Therapeutics (APGE), and Dianthus Therapeutics (DNTH). These companies are all part of the "pharmaceutical products" industry.

How does Septerna compare to Grifols?

Grifols (NASDAQ:GRFS) and Septerna (NASDAQ:SEPN) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, media sentiment, profitability, valuation, analyst recommendations, institutional ownership, earnings and risk.

In the previous week, Septerna had 2 more articles in the media than Grifols. MarketBeat recorded 4 mentions for Septerna and 2 mentions for Grifols. Grifols' average media sentiment score of 1.64 beat Septerna's score of -0.03 indicating that Grifols is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Grifols	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Septerna	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Grifols has a net margin of 5.54% compared to Septerna's net margin of -49.88%. Grifols' return on equity of 6.21% beat Septerna's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Grifols	5.54%	6.21%	2.39%
Septerna	-49.88%	-12.72%	-8.87%

Grifols has higher revenue and earnings than Septerna. Septerna is trading at a lower price-to-earnings ratio than Grifols, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Grifols	$8.51B	0.59	$454.82M	$0.19	38.58
Septerna	$45.95M	29.83	-$48.88M	-$0.81	N/A

Grifols currently has a consensus target price of $10.00, suggesting a potential upside of 36.43%. Septerna has a consensus target price of $45.00, suggesting a potential upside of 47.98%. Given Septerna's stronger consensus rating and higher probable upside, analysts clearly believe Septerna is more favorable than Grifols.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Grifols	1 Sell rating(s)	3 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.75
Septerna	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.80

Grifols has a beta of 0.65, meaning that its share price is 35% less volatile than the broader market. Comparatively, Septerna has a beta of 2.39, meaning that its share price is 139% more volatile than the broader market.

Summary

Grifols beats Septerna on 8 of the 15 factors compared between the two stocks.

How does Septerna compare to Xenon Pharmaceuticals?

Xenon Pharmaceuticals (NASDAQ:XENE) and Septerna (NASDAQ:SEPN) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, media sentiment, profitability, valuation, analyst recommendations, institutional ownership, earnings and risk.

Xenon Pharmaceuticals has a net margin of 0.00% compared to Septerna's net margin of -49.88%. Septerna's return on equity of -12.72% beat Xenon Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Xenon Pharmaceuticals	N/A	-49.23%	-46.42%
Septerna	-49.88%	-12.72%	-8.87%

95.5% of Xenon Pharmaceuticals shares are held by institutional investors. 4.1% of Xenon Pharmaceuticals shares are held by insiders. Comparatively, 4.3% of Septerna shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Xenon Pharmaceuticals has a beta of 0.62, indicating that its share price is 38% less volatile than the broader market. Comparatively, Septerna has a beta of 2.39, indicating that its share price is 139% more volatile than the broader market.

Xenon Pharmaceuticals currently has a consensus target price of $77.20, suggesting a potential upside of 50.75%. Septerna has a consensus target price of $45.00, suggesting a potential upside of 47.98%. Given Xenon Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Xenon Pharmaceuticals is more favorable than Septerna.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Xenon Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	14 Buy rating(s)	2 Strong Buy rating(s)	3.00
Septerna	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.80

Septerna has higher revenue and earnings than Xenon Pharmaceuticals. Septerna is trading at a lower price-to-earnings ratio than Xenon Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Xenon Pharmaceuticals	$7.50M	660.06	-$345.91M	-$4.70	N/A
Septerna	$45.95M	29.83	-$48.88M	-$0.81	N/A

In the previous week, Septerna had 2 more articles in the media than Xenon Pharmaceuticals. MarketBeat recorded 4 mentions for Septerna and 2 mentions for Xenon Pharmaceuticals. Xenon Pharmaceuticals' average media sentiment score of 0.85 beat Septerna's score of -0.03 indicating that Xenon Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Xenon Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Septerna	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Xenon Pharmaceuticals beats Septerna on 9 of the 17 factors compared between the two stocks.

How does Septerna compare to CG Oncology?

Septerna (NASDAQ:SEPN) and CG Oncology (NASDAQ:CGON) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, earnings, media sentiment, institutional ownership, analyst recommendations, profitability, dividends and risk.

In the previous week, Septerna and Septerna both had 4 articles in the media. Septerna's average media sentiment score of -0.03 beat CG Oncology's score of -0.37 indicating that Septerna is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Septerna	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
CG Oncology	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

CG Oncology has a net margin of 0.00% compared to Septerna's net margin of -49.88%. Septerna's return on equity of -12.72% beat CG Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Septerna	-49.88%	-12.72%	-8.87%
CG Oncology	N/A	-23.33%	-22.24%

Septerna has a beta of 2.39, indicating that its stock price is 139% more volatile than the broader market. Comparatively, CG Oncology has a beta of 0.31, indicating that its stock price is 69% less volatile than the broader market.

26.6% of CG Oncology shares are held by institutional investors. 4.3% of Septerna shares are held by company insiders. Comparatively, 4.8% of CG Oncology shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Septerna has higher revenue and earnings than CG Oncology. Septerna is trading at a lower price-to-earnings ratio than CG Oncology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Septerna	$45.95M	29.83	-$48.88M	-$0.81	N/A
CG Oncology	$4.04M	1,187.64	-$160.99M	-$2.33	N/A

Septerna presently has a consensus target price of $45.00, indicating a potential upside of 47.98%. CG Oncology has a consensus target price of $81.73, indicating a potential upside of 50.23%. Given CG Oncology's higher possible upside, analysts clearly believe CG Oncology is more favorable than Septerna.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Septerna	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.80
CG Oncology	1 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.71

Summary

Septerna beats CG Oncology on 9 of the 15 factors compared between the two stocks.

How does Septerna compare to Apogee Therapeutics?

Apogee Therapeutics (NASDAQ:APGE) and Septerna (NASDAQ:SEPN) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their risk, institutional ownership, earnings, dividends, media sentiment, valuation, profitability and analyst recommendations.

Apogee Therapeutics presently has a consensus target price of $114.56, indicating a potential upside of 38.01%. Septerna has a consensus target price of $45.00, indicating a potential upside of 47.98%. Given Septerna's stronger consensus rating and higher probable upside, analysts clearly believe Septerna is more favorable than Apogee Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Apogee Therapeutics	1 Sell rating(s)	5 Hold rating(s)	11 Buy rating(s)	2 Strong Buy rating(s)	2.74
Septerna	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.80

79.0% of Apogee Therapeutics shares are held by institutional investors. 24.3% of Apogee Therapeutics shares are held by insiders. Comparatively, 4.3% of Septerna shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Septerna has higher revenue and earnings than Apogee Therapeutics. Septerna is trading at a lower price-to-earnings ratio than Apogee Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Apogee Therapeutics	N/A	N/A	-$255.84M	-$4.33	N/A
Septerna	$45.95M	29.83	-$48.88M	-$0.81	N/A

Apogee Therapeutics has a beta of 0.62, suggesting that its share price is 38% less volatile than the broader market. Comparatively, Septerna has a beta of 2.39, suggesting that its share price is 139% more volatile than the broader market.

In the previous week, Apogee Therapeutics had 3 more articles in the media than Septerna. MarketBeat recorded 7 mentions for Apogee Therapeutics and 4 mentions for Septerna. Apogee Therapeutics' average media sentiment score of 0.62 beat Septerna's score of -0.03 indicating that Apogee Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Apogee Therapeutics	3 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Septerna	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Apogee Therapeutics has a net margin of 0.00% compared to Septerna's net margin of -49.88%. Septerna's return on equity of -12.72% beat Apogee Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Apogee Therapeutics	N/A	-32.64%	-31.25%
Septerna	-49.88%	-12.72%	-8.87%

Summary

Apogee Therapeutics and Septerna tied by winning 8 of the 16 factors compared between the two stocks.

How does Septerna compare to Dianthus Therapeutics?

Dianthus Therapeutics (NASDAQ:DNTH) and Septerna (NASDAQ:SEPN) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, institutional ownership, dividends, valuation, media sentiment, analyst recommendations, earnings and risk.

47.5% of Dianthus Therapeutics shares are owned by institutional investors. 3.0% of Dianthus Therapeutics shares are owned by company insiders. Comparatively, 4.3% of Septerna shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

In the previous week, Dianthus Therapeutics had 3 more articles in the media than Septerna. MarketBeat recorded 7 mentions for Dianthus Therapeutics and 4 mentions for Septerna. Dianthus Therapeutics' average media sentiment score of 0.50 beat Septerna's score of -0.03 indicating that Dianthus Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Dianthus Therapeutics	3 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Septerna	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Dianthus Therapeutics has a beta of 1.18, meaning that its stock price is 18% more volatile than the broader market. Comparatively, Septerna has a beta of 2.39, meaning that its stock price is 139% more volatile than the broader market.

Dianthus Therapeutics currently has a consensus target price of $117.82, indicating a potential upside of 45.06%. Septerna has a consensus target price of $45.00, indicating a potential upside of 47.98%. Given Septerna's higher possible upside, analysts clearly believe Septerna is more favorable than Dianthus Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Dianthus Therapeutics	1 Sell rating(s)	0 Hold rating(s)	11 Buy rating(s)	2 Strong Buy rating(s)	3.00
Septerna	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.80

Septerna has a net margin of -49.88% compared to Dianthus Therapeutics' net margin of -12,998.50%. Septerna's return on equity of -12.72% beat Dianthus Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Dianthus Therapeutics	-12,998.50%	-27.30%	-25.91%
Septerna	-49.88%	-12.72%	-8.87%

Septerna has higher revenue and earnings than Dianthus Therapeutics. Septerna is trading at a lower price-to-earnings ratio than Dianthus Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Dianthus Therapeutics	$2.04M	2,176.62	-$162.34M	-$4.13	N/A
Septerna	$45.95M	29.83	-$48.88M	-$0.81	N/A

Summary

Septerna beats Dianthus Therapeutics on 9 of the 16 factors compared between the two stocks.

Get Septerna News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SEPN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SEPN vs. The Competition

Export

Metric	Septerna	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$1.40B	$3.34B	$6.49B	$11.99B
Dividend Yield	N/A	2.30%	2.67%	5.57%
P/E Ratio	-37.54	10.38	20.24	21.95
Price / Sales	29.83	298.43	507.57	108.00
Price / Cash	N/A	51.45	26.99	37.25
Price / Book	3.57	8.04	10.28	6.78
Net Income	-$48.88M	$23.89M	$3.57B	$337.51M
7 Day Performance	1.43%	-5.97%	-1.43%	-2.72%
1 Month Performance	27.40%	2.78%	3.27%	1.87%
1 Year Performance	197.85%	36.26%	23.37%	26.61%

Septerna Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SEPN Septerna	2.3457 of 5 stars	$30.41 -2.4%	$45.00 +48.0%	+205.1%	$1.40B	$45.95M	N/A	N/A	News Coverage Analyst Forecast Gap Up
GRFS Grifols	4.5228 of 5 stars	$7.64 -1.4%	$10.00 +31.0%	-13.4%	$5.34B	$8.51B	40.48	25,247	Positive News
XENE Xenon Pharmaceuticals	3.8124 of 5 stars	$52.35 -2.0%	$77.20 +47.5%	+63.5%	$5.29B	N/A	N/A	210
CGON CG Oncology	2.9046 of 5 stars	$55.51 -6.3%	$81.73 +47.2%	+99.6%	$5.22B	$5.07M	N/A	61	Gap Up
APGE Apogee Therapeutics	3.194 of 5 stars	$78.92 -0.5%	$113.63 +44.0%	+112.1%	$5.08B	N/A	N/A	91	Analyst Forecast Insider Trade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SEPN) was last updated on 6/8/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Septerna (SEPN) Competitors

SEPN vs. GRFS, XENE, CGON, APGE, and DNTH

How does Septerna compare to Grifols?

Summary

How does Septerna compare to Xenon Pharmaceuticals?

Summary

How does Septerna compare to CG Oncology?

Summary

How does Septerna compare to Apogee Therapeutics?

Summary

How does Septerna compare to Dianthus Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SEPN vs. The Competition

Septerna Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Septerna (SEPN) Competitors

SEPN vs. GRFS, XENE, CGON, APGE, and DNTH

How does Septerna compare to Grifols?

Does the media refer more to GRFS or SEPN?

Is GRFS or SEPN more profitable?

Which has higher valuation & earnings, GRFS or SEPN?

Do analysts rate GRFS or SEPN?

Which has more risk and volatility, GRFS or SEPN?

Summary

How does Septerna compare to Xenon Pharmaceuticals?

Is XENE or SEPN more profitable?

Do insiders and institutionals hold more shares of XENE or SEPN?

Which has more volatility and risk, XENE or SEPN?

Do analysts rate XENE or SEPN?

Which has higher valuation & earnings, XENE or SEPN?

Does the media refer more to XENE or SEPN?

Summary

How does Septerna compare to CG Oncology?

Does the media prefer SEPN or CGON?

Is SEPN or CGON more profitable?

Which has more volatility and risk, SEPN or CGON?

Do institutionals and insiders believe in SEPN or CGON?

Which has better earnings and valuation, SEPN or CGON?

Do analysts prefer SEPN or CGON?

Summary

How does Septerna compare to Apogee Therapeutics?

Do analysts prefer APGE or SEPN?

Do insiders and institutionals believe in APGE or SEPN?

Which has stronger earnings & valuation, APGE or SEPN?

Which has more risk & volatility, APGE or SEPN?

Does the media refer more to APGE or SEPN?

Is APGE or SEPN more profitable?

Summary

How does Septerna compare to Dianthus Therapeutics?

Do insiders & institutionals believe in DNTH or SEPN?

Does the media favor DNTH or SEPN?

Which has more risk & volatility, DNTH or SEPN?

Do analysts rate DNTH or SEPN?

Is DNTH or SEPN more profitable?

Which has stronger earnings and valuation, DNTH or SEPN?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SEPN vs. The Competition

Septerna Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools